Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com

StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note issued to investors on Wednesday. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

Shares of NYSE:BTX opened at $1.12 on Wednesday. The company’s fifty day moving average price is $1.26 and its 200-day moving average price is $1.66. The firm has a market capitalization of $65.89 million, a price-to-earnings ratio of -0.49 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a one year low of $0.17 and a one year high of $10.10.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.